Found a bug or want a feature? Verified reports earn free credits.
Log inSign up
Companies›Healthcare›Healthcare›Pharmaceuticals & Biotechnology
NSE:SUNLOC

SUNIL HEALTHCARE LTD.

Healthcare › Pharmaceuticals & Biotechnology
₹72.50
at close · 8 Oct 2026
▲ 2.50 (+3.57%)

Latest filings

  1. Credit Rating Upgraded to BBB-/A3 by Brickwork · Credit & Debt
  2. 52nd AGM results: all resolutions passed with requisite majority · Board & Shareholder Meetings
  3. Sunil Healthcare 52nd AGM proceedings held on September 28, 2026 · Board & Shareholder Meetings
All filings ↓
Ask Nexa about SUNIL HEALTHCARE LTD.

Snapshot

What the business is, and whether it's a good one at a fair price.

AI · written from filings

Makes pharmaceutical capsules from three manufacturing units — Bajaj Healthcare, Hindustan Pharmacy and an Ayurvedic/cosmeceuticals division — and sells them as its only revenue-generating segment, with capsules accounting for 100% of segment revenue in the period reported (F_SEGMENTS, F_FILINGS 2026-05-31). FY26 consolidated revenue was Rs 87.7192 crore (F_SCALE). On the cost side, materials make up 37.1% of revenue, other operating expenses 33.4%, employee costs 14.7% and depreciation 7.3%, with capex at 4.1% of revenue (F_COST_SHAPE). The business also runs two foreign subsidiaries — Sunil Healthcare Mexico SA De CV and Sunil Healthcare North America LLC — which contributed negligible revenue but around Rs 97 lakhs of consolidated net profit in the nine-month period of FY26 (F_FILINGS 2026-02-06). FY26 consolidated net profit was Rs 4.006 crore on an EBITDA margin of 16.9% (F_SCALE). The marketing of food products line was a discontinued operation (F_SEGMENTS).

Revenue mix · reported segments
Capsules100.0%
Marketing of Food Products0.0%
Operating scale
Manufacturing units
3 (Bajaj Healthcare, Hindustan Pharmacy, Ayurvedic/cosmeceuticals)FY26
Foreign subsidiaries
2 (Mexico SA De CV, North America LLC)FY26
FY26 consolidated revenue
Rs 87.72 croreFY26
Capsule share of segment revenue
100%FY26
EBITDA margin
16.9%FY26
Capex as % of revenue
4.1%FY26
Who pays it
Pharmaceutical buyers — drug companies and distributors of capsule formulations
Biggest cost
Materials at 37.1% of revenue, the single largest input cost
Kind of business
Small-cap, single-segment pharmaceutical formulations manufacturer
Where it sits
BSE-listed pharmaceutical company operating three manufacturing units and two foreign subsidiaries
Market Cap
₹73 Cr
P / E (TTM)
18.3×
EV / EBITDA
8.7×
Div Yield
—
Growth
-0.6%▼
Revenue 5y CAGR
PAT — · EBITDA +6.4%
Quality
8.6%·
ROCE (5y median)
ROE 5.8% (5y median) · margin 16.9%
Leverage
0.80·
Debt / Equity · moderate
Net debt ₹56 Cr
Revenue FY21→FY26
1.0×▼
Margin +5.3 pts
₹90 Cr → ₹88 Cr
Cash conversion
3.45×▲
Operating cash ÷ profit · 5 yrs
₹48 Cr on ₹14 Cr
Where it sits among 185 Pharmaceuticals peersBar = share of peers beaten · tick = industry median · latest reported figures
P/E (TTM)#39/158
P/B#21/163
ROCE#141/183
ROE#112/166
Debt / Equity#150/166
EBITDA margin#114/165
Revenue growth#131/161
Profit growth#17/158

Scorecard

Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice

Strengths
Over 5 years it reported ₹14 Cr of profit and ₹48 Cr of operating cash — 3.45×
Profit is converting into cash
Concerns
Revenue shrinking over 5 years (−1% a year)
Carries more debt than its peers — 0.80× equity
higher than 90% of its 166 Pharmaceuticals peers
Heavy working capital — 199 days of cash tied up
Customers are taking longer to pay — 95 → 188 days of receivables
FY21 → FY26

Charts

How has the market priced it — with filings on the timeline?

SUNLOC · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Peers

How does it stack up on valuation, returns and growth?

Loading peers…

Financials

Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.

Loading financials…

Ownership

Who owns it — and is the promoter stake clean?

Loading shareholding…

Sign up to see the full company file

Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.

Common questions

Answered from SUNIL HEALTHCARE LTD.'s filed financials and exchange disclosures

What does SUNIL HEALTHCARE LTD. do?

SUNIL HEALTHCARE LTD. is a Pharmaceuticals & Biotechnology company listed on NSE and BSE, trading under the symbol SUNLOC.

Is SUNIL HEALTHCARE LTD. profitable?

Yes. Over the trailing twelve months SUNIL HEALTHCARE LTD. reported a net profit of ₹4.01 Cr on revenue of ₹88 Cr.

Does SUNIL HEALTHCARE LTD. pay a dividend?

Not in the latest reported year — SUNIL HEALTHCARE LTD.'s dividend payout for FY26 was nil.

Is SUNIL HEALTHCARE LTD. debt-free?

No. It reported borrowings of ₹56 Cr on its 31 Mar 2026 balance sheet, or net debt of ₹56 Cr after cash. Debt stands at 0.80× equity. That is higher than 90% of its 166 Pharmaceuticals peers.

Is SUNIL HEALTHCARE LTD. expensive compared with its peers?

On trailing P/E, SUNIL HEALTHCARE LTD. ranks 39 of 158 in Pharmaceuticals — cheaper than 76% of them, against an industry median of 32.1×. This is a position, not a valuation judgement.

Where can I track SUNIL HEALTHCARE LTD.'s announcements?

Every NSE and BSE filing by SUNIL HEALTHCARE LTD. appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.

Figures are as last reported and may lag the latest filing. Not investment advice.